Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott’s investigational Coronary ...

SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...

SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...

Johnson & Johnson (J&J) MedTech’s Shockwave Medical has commenced the multicentre, prospective FORWARD CAD investigational device exemption (IDE) study of the Javelin coronary intravascular ...

Add Yahoo as a preferred source to see more of our stories on Google. Kevin Wininger, a computed tomography technologist and cardiovascular technologist at University Hospital’s Samaritan Medical ...

After its Diamondback 360 orbital atherectomy approach failed to clear a large trial in coronary artery disease last year, Abbott will shift to the TECTONIC trial and its unnamed intravascular ...

Approvals Cover Both Coronary and Peripheral IVL Catheters and Generators Manufactured by Shockwave About Shockwave Medical, Inc.Shockwave is focused on developing and commercializing products ...

Next-generation intravascular lithotripsy (IVL) catheter resets physicians’ expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioning Shockwave C2 Aero ...

Abbott Laboratories emphatically let Boston Scientific and Johnson & Johnson know it wanted a piece of the intravascular lithotripsy (IVL) space. The Abbott Park, IL-based company reported FDA had ...

As medtech companies eye entry into the IVL space, Shockwave Medical is consolidating its position through innovation and ...

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass.

Results from the first randomized controlled trial to directly compare the safety and efficacy of cutting balloon (CB) angioplasty to intravascular lithotripsy (IVL) prior to drug-eluting stent (DES) ...